Board Change • Mar 02
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 4 independent directors (6 non-independent directors). Director Junyi Li was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공시 • Jan 30
Pharmigene, Inc., Annual General Meeting, Jun 15, 2026 Pharmigene, Inc., Annual General Meeting, Jun 15, 2026. Location: 3 floor no,302, chien kuo 1st rd., sinjhuang district, new taipei city Taiwan New Risk • Aug 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$86m free cash flow). Earnings have declined by 35% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Revenue is less than US$5m (NT$149m revenue, or US$4.9m). Market cap is less than US$100m (NT$570.3m market cap, or US$18.8m). Reported Earnings • Aug 15
First half 2025 earnings released: NT$0.82 loss per share (vs NT$0.96 loss in 1H 2024) First half 2025 results: NT$0.82 loss per share (improved from NT$0.96 loss in 1H 2024). Revenue: NT$80.7m (up 68% from 1H 2024). Net loss: NT$41.3m (loss narrowed 15% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Board Change • Jun 23
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). Director Junyi Li was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 19
Full year 2024 earnings released: NT$1.64 loss per share (vs NT$1.60 loss in FY 2023) Full year 2024 results: NT$1.64 loss per share (further deteriorated from NT$1.60 loss in FY 2023). Revenue: NT$116.5m (down 12% from FY 2023). Net loss: NT$82.9m (loss widened 14% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. 공시 • Mar 12
Pharmigene, Inc., Annual General Meeting, Jun 03, 2025 Pharmigene, Inc., Annual General Meeting, Jun 03, 2025. Location: 3 floor no,302, chien kuo 1st rd., sinjhuang district, new taipei city Taiwan New Risk • Feb 28
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$143m free cash flow). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (NT$127m revenue, or US$3.9m). Market cap is less than US$100m (NT$683.8m market cap, or US$20.8m). Reported Earnings • Aug 18
First half 2024 earnings released: NT$0.96 loss per share (vs NT$0.66 loss in 1H 2023) First half 2024 results: NT$0.96 loss per share (further deteriorated from NT$0.66 loss in 1H 2023). Revenue: NT$47.9m (down 11% from 1H 2023). Net loss: NT$48.7m (loss widened 70% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Reported Earnings • May 04
Full year 2023 earnings released: NT$1.60 loss per share (vs NT$0.98 loss in FY 2022) Full year 2023 results: NT$1.60 loss per share (further deteriorated from NT$0.98 loss in FY 2022). Revenue: NT$132.7m (flat on FY 2022). Net loss: NT$72.6m (loss widened 70% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. 공시 • Apr 12
Pharmigene, Inc., Annual General Meeting, Jun 24, 2024 Pharmigene, Inc., Annual General Meeting, Jun 24, 2024. New Risk • Feb 24
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$132m revenue, or US$4.2m). Market cap is less than US$100m (NT$1.03b market cap, or US$32.6m). New Risk • Oct 24
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$132m revenue, or US$4.1m). Market cap is less than US$100m (NT$1.16b market cap, or US$35.9m). Reported Earnings • Aug 14
First half 2023 earnings released: NT$0.66 loss per share (vs NT$0.53 loss in 1H 2022) First half 2023 results: NT$0.66 loss per share (further deteriorated from NT$0.53 loss in 1H 2022). Revenue: NT$53.6m (down 2.7% from 1H 2022). Net loss: NT$28.7m (loss widened 25% from 1H 2022). New Risk • Aug 09
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$681m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$132m revenue, or US$4.2m). Market cap is less than US$100m (NT$1.06b market cap, or US$33.4m). Reported Earnings • Apr 07
Full year 2022 earnings released: NT$0.98 loss per share (vs NT$0.54 loss in FY 2021) Full year 2022 results: NT$0.98 loss per share (further deteriorated from NT$0.54 loss in FY 2021). Revenue: NT$133.8m (up 3.4% from FY 2021). Net loss: NT$42.7m (loss widened 82% from FY 2021). Reported Earnings • Apr 12
Full year 2021 earnings released: NT$0.54 loss per share (vs NT$0.33 loss in FY 2020) Full year 2021 results: NT$0.54 loss per share (down from NT$0.33 loss in FY 2020). Revenue: NT$129.4m (up 28% from FY 2020). Net loss: NT$23.4m (loss widened 109% from FY 2020).